The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Universities are waiting cautiously as the agency's unilateral plan to cut billions of research support dollars has already ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

Today, a brief rundown of news involving Amgen and the Parker Institute, as well as updates from J&J, Alzheon and Amylyx Pharmaceuticals that you may have missed.

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

Novartis’ expansion will substantially boost its capital spending, which has run around $1 billion the past several years. It will also broaden Novartis’ commercial footprint, adding six new ...

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...